Drug Trial Radar · NCT07933783
An Open-label Study With Maintenance Dosing of ORKA-002 in Participants With Moderate-to-Severe Plaque Psoriasis
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
160
Planned (sponsor's estimate)
Start
Oct 26, 2026
Primary completion
Jul 1, 2029
Study completion Sep 1, 2029
Sponsor
- Lead sponsor
- Oruka Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 79 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An open-label study with maintenance dosing to evaluate the long-term safety and efficacy of ORKA-002 in adult participants with moderate-to-severe plaque psoriasis, who previously participated in an Oruka Therapeutics sponsored study.
Conditions
- Plaque Psoriasis
Interventions
ORKA-002Drug
ORKA-002 administered by subcutaneous (SC) injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and TEAEs of Special Interest (TEAESIs)Time frame: Day 1 through Week 144
Locations
8 sites in 2 countries. Site status is shown where the registry gives one.
Oruka Therapeutics Investigative Site
Fountain Valley, California
Oruka Therapeutics Investigative Site
Milford, Massachusetts
Oruka Therapeutics Investigative Site
New Brighton, Minnesota
Oruka Therapeutics Investigative Site
Wilmington, North Carolina
Oruka Therapeutics Investigative Site
Warrenton, Oregon
Oruka Therapeutics Investigative Site
Barrie, Ontario, Canada
Oruka Therapeutics Investigative Site
North Bay, Ontario, Canada
Oruka Therapeutics Investigative Site
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.